XBIT vs. AURA, TKNO, RCKT, AVTE, GLUE, PRME, OLMA, AVIR, ADCT, and TRDA
Should you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Aura Biosciences (AURA), Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), Aerovate Therapeutics (AVTE), Monte Rosa Therapeutics (GLUE), Prime Medicine (PRME), Olema Pharmaceuticals (OLMA), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry.
XBiotech vs. Its Competitors
Aura Biosciences (NASDAQ:AURA) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Aura Biosciences presently has a consensus price target of $22.00, indicating a potential upside of 233.84%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aura Biosciences is more favorable than XBiotech.
In the previous week, Aura Biosciences and Aura Biosciences both had 1 articles in the media. XBiotech's average media sentiment score of 0.59 beat Aura Biosciences' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media.
96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by company insiders. Comparatively, 33.1% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Aura Biosciences has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
XBiotech has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.
XBiotech's return on equity of -21.14% beat Aura Biosciences' return on equity.
Summary
XBiotech beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.
Get XBiotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XBiotech Competitors List
Related Companies and Tools
This page (NASDAQ:XBIT) was last updated on 7/5/2025 by MarketBeat.com Staff
Free XBIT Stock Alerts